Exhibit 99.1

                      VASO ACTIVE BEGINS SHIPPING PRODUCT
                      -----------------------------------

                  DANVERS, Mass. - (Business Wire) - July 7, 2006 - Vaso Active
Pharmaceuticals, Inc. ("Vaso Active") (VAPH.ob) announced today that it has
begun shipping its AR-Extreme(r), Osteon(r), and Termin8(r) products that
utilize its PentoCore technology, through its brokerage agreement with the
Ferolie Group of Montvale, New Jersey. Through that agreement Vaso Active has
shipped products under purchase order to Harmon Discount Stores, a Bed Bath and
Beyond subsidiary. In additionVaso Active has shipped products to Kinray, Inc.,
a distributor of pharmaceutical, health and beauty products to over 3,000
independent retailers in the northeast.

                  "Shipping product through the brokerage agreement with Ferolie
reflects that Vaso Active is moving forward with its strategy for distribution
and market penetration." stated Joseph Frattaroli, President and CFO of Vaso
Active.

         Vaso Active Pharmaceuticals, Inc, is an early stage company that
focuses on commercializing, marketing and selling over-the-counter
pharmaceutical products that incorporate either a patented transdermal
technology ("VALE") or a proprietary topical technology ("PENtoCORE").

         The unique VALE technology is intended to be a patchless, lipid-based
delivery system that uses an active process, incorporating chemical
vasodilators, to deliver drugs through the skin and into the bloodstream.
Products utilizing this technology are currently in development through
BioChemics, Inc.

         The PENtoCORE technology is a topical formulation and the Company is
currently marketing three products that incorporate this technology: OSTEON (for
temporary relief from minor arthritis pain), A-R EXTREME (for temporary relief
from minor muscle and joint pain associated with athletic activity) and TERMIN8
(for athlete's foot fungal infections).





FORWARD-LOOKING STATEMENTS
Certain statements contained herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations, estimates
and projections about the Company's industry, management's beliefs and certain
assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Because such statements involve risks and uncertainties, the actual
results and performance of the Company may differ materially from the results
expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Unless otherwise required by law, the Company also
disclaims any obligation to update its view of any such risks or uncertainties
or to announce publicly the result of any revisions to the forward-looking
statements made here; however, readers should review carefully reports of
documents the Company files periodically with the SEC.

Contact:
- --------
Matt Carter
Vaso Active Pharmaceuticals, Inc.
978-750-1991 Ext. 28
         mcarter@vasoactive.us
         ---------------------